JAVELIN Merkel 200: Results of Phase II Study for Merkel Cell Carcinoma

Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey gives an overview of his current research, a phase II study which involved a newly FDA-approved drug, avelumab, in patients with m... Author: aacr2017 Added: 04/27/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts